Shareprice
27 May 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

In connection with the Directed Share Issue dated the 10 of March 2022, Life Science ApS have agreed to lend 142,000 shares to ABG Sundal Collier AB in order to facilitate delivery of the shares.

Press release


March 17, 2022

Copenhagen, Denmark, 17 March 2022 – FluoGuide A/S (publ) a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”) (Nasdaq First North Growth Market: FLUO) hereby announces that in connection with the Directed Share Issue dated the 10 of March 2022, Andreas Kjær through Life Science ApS have agreed to lend 142,000 shares to ABG Sundal Collier AB in order to facilitate delivery of the shares. The shares will be returned in connection with the Directed Share Issue being registered with the Danish Business Authority.

For more information contact:

FluoGuide A/S

 Henrik Moltke, CFO
+45 22 44 54 04
hm@fluoguide.com

 Certified adviser:

Svensk Kapitalmarknadsgranskning AB
+46 70 755 95 51
ca@skmg.se

 

About FluoGuide

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated early evidence of efficacy of F001 as well as it to be well tolerated and safe in the ongoing proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.